UBS Group reiterated their sell rating on shares of AstraZeneca (LON:AZN) in a report issued on Monday, Borsen Zeitung reports. UBS Group currently has a GBX 5,800 ($76.30) price target on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the company. Morgan Stanley raised their price target on AstraZeneca from GBX 7,400 ($97.34) to GBX 8,100 ($106.55) and gave the company an equal weight rating in a research note on Monday, January 6th. Liberum Capital reiterated a buy rating on shares of AstraZeneca in a research report on Friday, February 14th. JPMorgan Chase & Co. set a GBX 8,500 ($111.81) target price on AstraZeneca and gave the stock a buy rating in a research report on Friday, February 14th. Citigroup reiterated a buy rating on shares of AstraZeneca in a research report on Tuesday, January 28th. Finally, Goldman Sachs Group set a GBX 6,000 ($78.93) target price on AstraZeneca and gave the stock a sell rating in a research report on Friday, February 14th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating to the company. AstraZeneca currently has a consensus rating of Buy and an average target price of GBX 7,890.71 ($103.80).

AstraZeneca stock opened at GBX 7,604 ($100.03) on Monday. AstraZeneca has a 1-year low of GBX 109.51 ($1.44) and a 1-year high of GBX 8,227.88 ($108.23). The company has a debt-to-equity ratio of 148.59, a current ratio of 0.92 and a quick ratio of 0.70. The stock has a market cap of $99.39 billion and a PE ratio of 47.70. The stock’s fifty day moving average is GBX 7,630.50 and its two-hundred day moving average is GBX 7,357.78.

The company also recently announced a dividend, which will be paid on Monday, March 30th. Stockholders of record on Thursday, February 27th will be given a dividend of GBX 146.40 ($1.93) per share. The ex-dividend date of this dividend is Thursday, February 27th. This represents a dividend yield of 1.92%. This is a boost from AstraZeneca’s previous dividend of $71.90. AstraZeneca’s payout ratio is 1.37%.

In other news, insider Michel Demare bought 700 shares of the business’s stock in a transaction dated Monday, February 17th. The shares were acquired at an average price of GBX 7,313 ($96.20) per share, for a total transaction of £51,191 ($67,338.86).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Further Reading: What does the Producer Price Index (PPI) tell investors?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.